Literature DB >> 26951453

No evidence of increased breast cancer risk for proven noncarriers from BRCA1 and BRCA2 families.

Henriette Roed Nielsen1, Janne Petersen2,3, Lotte Krogh4, Mef Nilbert2,5, Anne-Bine Skytte6.   

Abstract

In families screened for mutations in the BRCA1 or BRCA2 genes and found to have a segregating mutation the breast cancer risk for women shown not to carry the family-specific mutation might be at above "average" risk. We assessed the risk of breast cancer in a clinic based cohort of 725 female proven noncarriers in 239 BRCA1 and BRCA2 families compared with birth-matched controls from the Danish Civil Registration System. Prospective analysis showed no significantly increased risk for breast cancer in noncarriers with a hazard ratio of 0.67 [95 % confidence interval (CI) 0.32-1.42, p = 0.29] for all family members who tested negative and 0.87 (95 % CI 0.38-1.97, p = 0.73) for non-carries who were first-degree relatives of mutation carriers. Proven noncarriers from BRCA1 and BRCA2 families have no markedly increased risk for breast cancer compared to the general population, and our data do not suggest targeted breast cancer surveillance for noncarriers from BRCA1 and BRCA2 families.

Entities:  

Keywords:  Female cancer risk; HBOC; Hereditary cancer; Modifiers; Phenocopies

Mesh:

Substances:

Year:  2016        PMID: 26951453     DOI: 10.1007/s10689-016-9898-0

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  17 in total

1.  No evidence of excess breast cancer risk among mutation-negative women from BRCA mutation-positive families.

Authors:  Larissa A Korde; Christine M Mueller; Jennifer T Loud; Jeffery P Struewing; Kathy Nichols; Mark H Greene; Phuong L Mai
Journal:  Breast Cancer Res Treat       Date:  2010-05-11       Impact factor: 4.872

2.  Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2.

Authors:  S M Domchek; M M Gaudet; J E Stopfer; M H Fleischaut; J Powers; N Kauff; K Offit; K L Nathanson; M Robson
Journal:  Breast Cancer Res Treat       Date:  2010-01       Impact factor: 4.872

3.  Phenocopy breast cancer rates in Israeli BRCA1 BRCA2 mutation carrier families: is the risk increased in non-carriers?

Authors:  Shiri Bernholtz; Yael Laitman; Bella Kaufman; Shnai Shimon-Paluch; Eitan Friedman
Journal:  Breast Cancer Res Treat       Date:  2011-11-24       Impact factor: 4.872

4.  Cancer risks in BRCA2 mutation carriers.

Authors: 
Journal:  J Natl Cancer Inst       Date:  1999-08-04       Impact factor: 13.506

5.  Breast cancer risk for noncarriers of family-specific BRCA1 and BRCA2 mutations: findings from the Breast Cancer Family Registry.

Authors:  Allison W Kurian; Gail D Gong; Esther M John; David A Johnston; Anna Felberg; Dee W West; Alexander Miron; Irene L Andrulis; John L Hopper; Julia A Knight; Hilmi Ozcelik; Gillian S Dite; Carmel Apicella; Melissa C Southey; Alice S Whittemore
Journal:  J Clin Oncol       Date:  2011-10-31       Impact factor: 44.544

6.  Phenocopies in breast cancer 1 (BRCA1) families: implications for genetic counselling.

Authors:  Jacek Gronwald; Cezary Cybulski; Jan Lubinski; Steven A Narod
Journal:  J Med Genet       Date:  2007-04       Impact factor: 6.318

7.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.

Authors:  D Ford; D F Easton; M Stratton; S Narod; D Goldgar; P Devilee; D T Bishop; B Weber; G Lenoir; J Chang-Claude; H Sobol; M D Teare; J Struewing; A Arason; S Scherneck; J Peto; T R Rebbeck; P Tonin; S Neuhausen; R Barkardottir; J Eyfjord; H Lynch; B A Ponder; S A Gayther; M Zelada-Hedman
Journal:  Am J Hum Genet       Date:  1998-03       Impact factor: 11.025

8.  Proven non-carriers in BRCA families have an earlier age of onset of breast cancer.

Authors:  Janet R Vos; Geertruida H de Bock; Natalia Teixeira; Dorina M van der Kolk; Liesbeth Jansen; Marian J E Mourits; Jan C Oosterwijk
Journal:  Eur J Cancer       Date:  2013-03-13       Impact factor: 9.162

9.  BRCA1/BRCA2 founder mutations and cancer risks: impact in the western Danish population.

Authors:  Henriette Roed Nielsen; Mef Nilbert; Janne Petersen; Steen Ladelund; Mads Thomassen; Inge Søkilde Pedersen; Thomas V O Hansen; Anne-Bine Skytte; Åke Borg; Christina Therkildsen
Journal:  Fam Cancer       Date:  2016-10       Impact factor: 2.375

10.  Increased rate of phenocopies in all age groups in BRCA1/BRCA2 mutation kindred, but increased prospective breast cancer risk is confined to BRCA2 mutation carriers.

Authors:  D Gareth R Evans; Sarah L Ingham; Iain Buchan; Emma R Woodward; Helen Byers; Anthony Howell; Eamonn R Maher; William G Newman; Fiona Lalloo
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-11-27       Impact factor: 4.254

View more
  3 in total

1.  Analysis of chromosomal radiosensitivity of healthy BRCA2 mutation carriers and non-carriers in BRCA families with the G2 micronucleus assay.

Authors:  Annelot Baert; Julie Depuydt; Tom Van Maerken; Bruce Poppe; Fransiska Malfait; Tim Van Damme; Sylvia De Nobele; Gianpaolo Perletti; Kim De Leeneer; Kathleen B M Claes; Anne Vral
Journal:  Oncol Rep       Date:  2017-01-25       Impact factor: 3.906

2.  Revertant mosaicism for family mutations is not observed in BRCA1/2 phenocopies.

Authors:  Jacopo Azzollini; Chiara Pesenti; Luca Ferrari; Laura Fontana; Mariarosaria Calvello; Bernard Peissel; Giorgio Portera; Silvia Tabano; Maria Luisa Carcangiu; Paola Riva; Monica Miozzo; Siranoush Manoukian
Journal:  PLoS One       Date:  2017-02-15       Impact factor: 3.240

3.  Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study.

Authors:  Fabio Girardi; Daniel R Barnes; Daniel Barrowdale; Debra Frost; Angela F Brady; Claire Miller; Alex Henderson; Alan Donaldson; Alex Murray; Carole Brewer; Caroline Pottinger; D Gareth Evans; Diana Eccles; Fiona Lalloo; Helen Gregory; Jackie Cook; Jacqueline Eason; Julian Adlard; Julian Barwell; Kai Ren Ong; Lisa Walker; Louise Izatt; Lucy E Side; M John Kennedy; Marc Tischkowitz; Mark T Rogers; Mary E Porteous; Patrick J Morrison; Ros Eeles; Rosemarie Davidson; Katie Snape; Douglas F Easton; Antonis C Antoniou
Journal:  Genet Med       Date:  2018-03-22       Impact factor: 8.822

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.